What peri‑operative management is recommended for a patient with chronic tophaceous gout undergoing a major surgery?

Perioperative Management for Chronic Tophaceous Gout Undergoing Major Surgery

Continue urate-lowering therapy (ULT) through the perioperative period without interruption, and initiate or optimize anti-inflammatory prophylaxis starting at least 1-2 weeks before surgery to prevent postoperative gout flares.

Pre-operative Optimization

Urate-Lowering Therapy Management

• Do NOT stop ULT (allopurinol, febuxostat, or other agents) before surgery 1
• Patients with chronic tophaceous gout require lifelong ULT to maintain serum uric acid (SUA) <5 mg/dL (300 mmol/L) for crystal dissolution 1
• Interrupting ULT risks precipitating acute flares in the vulnerable perioperative period
• Ensure SUA levels are at target before elective surgery when possible

Flare Prophylaxis (Critical Component)

Start prophylactic colchicine 0.5-1 mg daily at least 1-2 weeks before surgery and continue for 6 months postoperatively 1. This is the single most important intervention to prevent devastating postoperative flares.

Dose adjustments:

• Reduce colchicine dose with renal impairment (CrCl <50 mL/min: 0.5 mg daily or every other day)
• Avoid colchicine if patient takes strong P-glycoprotein/CYP3A4 inhibitors (cyclosporine, clarithromycin) 1
• If colchicine contraindicated: use low-dose NSAID with PPI (if renal function permits) 1

Timing Considerations

The 2022 ACR/AAHKS guideline addresses perioperative management of antirheumatic medications but does not include gout medications 2. This absence reflects that ULT agents (xanthine oxidase inhibitors, uricosurics) are not immunosuppressive and should be continued.

Intraoperative Considerations

Surgical Planning for Tophi

If surgery involves tophaceous tissue directly:

• Coordinate with surgical team about extent of tophi involvement
• Large tophi (>1.5 cm) causing functional impairment, chronic wounds, or joint destruction may warrant concurrent debridement 3, 4, 5
• Avoid elective tophus surgery during acute flares 4
• Consider staged procedures if extensive debridement needed

Infection Risk

• Tophi have bacteriostatic properties; infection rates in ulcerated tophi are relatively low (16% preoperative culture positivity) 4
• Standard surgical antibiotic prophylaxis is appropriate
• Most common organism when infected: Staphylococcus aureus 4

Post-operative Management

Acute Flare Treatment Protocol

Have a pre-planned flare management strategy ready:

If acute flare occurs despite prophylaxis:

1. First-line options (choose based on contraindications) 1:

   • Colchicine 1 mg loading dose, then 0.5 mg one hour later (if within 12 hours of flare onset)
   • NSAID + PPI (avoid if severe renal impairment, CrCl <30)
   • Oral prednisone 30-35 mg daily for 3-5 days
   • Joint aspiration + intra-articular corticosteroid injection

2. Second-line (if contraindications to above):

   • IL-1 blockers (anakinra, canakinumab) - but avoid if active infection 1

Continue ULT Optimization

• Monitor SUA levels postoperatively
• Titrate ULT dose upward if not at target (<5 mg/dL for tophaceous disease) 1
• Do not stop or reduce ULT dose due to surgery

Wound Healing Monitoring

For patients with tophi near surgical site:

• Wound complications occur in ~28% when tophi are surgically excised 6
• Monitor for wound dehiscence and infection
• Mean healing time approximately 31 days for tophaceous wounds 4

Critical Pitfalls to Avoid

1. Never discontinue ULT perioperatively - This is the most common error and precipitates severe flares
2. Never start ULT de novo in the immediate perioperative period - If patient not on ULT, wait 2-4 weeks post-surgery to initiate
3. Never skip flare prophylaxis - Postoperative flares are devastating and preventable
4. Never use colchicine at high doses - Low doses (0.5-1 mg/day) are sufficient and safer 1
5. Never operate during acute flare - Defer elective surgery until flare resolves

Special Populations

Renal Impairment (Common in Tophaceous Gout)

• Adjust allopurinol dose to creatinine clearance 1
• Reduce colchicine prophylaxis dose
• Avoid NSAIDs if CrCl <30 mL/min
• Consider febuxostat as alternative (no dose adjustment needed) 1

Severe Tophaceous Disease

• These patients have highest flare risk perioperatively
• Consider more aggressive prophylaxis (combination therapy may be needed)
• Multidisciplinary coordination essential 3, 7

The fundamental principle: Perioperative gout management prioritizes flare prevention through continued ULT and prophylactic anti-inflammatory therapy, not medication interruption.